These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 31076203)

  • 21. Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100, a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, double-blind study in healthy adults.
    Bodie S; Curran AK; Gonzalez-Nelson AC; Perry JM; Manning DC; Wasilewski MM
    Headache; 2024 Jun; 64(6):643-651. PubMed ID: 38717120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In Vitro, Pharmacokinetic, Pharmacodynamic, and Safety Comparisons of Single and Combined Administration of Tiotropium and Salmeterol in COPD Patients Using Different Dry Powder Inhalers.
    Horhota ST; van Noord JA; Verkleij CB; Bour LJ; Sharma A; Trunk M; Cornelissen PJ
    AAPS J; 2015 Jul; 17(4):871-80. PubMed ID: 25794622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pharmacokinetics, safety, and tolerability of single, high-strength doses of fluticasone propionate and fluticasone propionate/salmeterol delivered via a novel multidose dry powder inhaler in adolescents and adults with persistent asthma.
    Nugent C; Yiu G; Song S; Caracta C
    J Asthma; 2018 Aug; 55(8):898-906. PubMed ID: 28933971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-ranging study of salmeterol using a novel fluticasone propionate/salmeterol multidose dry powder inhaler in patients with persistent asthma.
    Miller DS; Yiu G; Hellriegel ET; Steinfeld J
    Allergy Asthma Proc; 2016 Jul; 37(4):291-301. PubMed ID: 27216137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta Syndrome.
    Begg M; Amour A; Jarvis E; Tang T; Franco SS; Want A; Beerahee M; Fernando D; Karkera Y; Sander C; Southworth T; Singh D; Clark J; Nejentsev S; Okkenhaug K; Condliffe A; Chandra A; Cahn A; Hall EB
    Pulm Pharmacol Ther; 2023 Apr; 79():102201. PubMed ID: 36841351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
    Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Translation of Inhaled Drug Optimization Strategies into Clinical Pharmacokinetics and Pharmacodynamics Using GSK2292767A, a Novel Inhaled Phosphoinositide 3-Kinase
    Begg M; Edwards CD; Hamblin JN; Pefani E; Wilson R; Gilbert J; Vitulli G; Mallett D; Morrell J; Hingle MI; Uddin S; Ehtesham F; Marotti M; Harrell A; Newman CF; Fernando D; Clark J; Cahn A; Hessel EM
    J Pharmacol Exp Ther; 2019 Jun; 369(3):443-453. PubMed ID: 30940692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of a 12-week therapy with a new formulation of fluticasone propionate at doses of 125 and 250 μg administered through a new generation cyclohaler twice daily, in comparison to fluticasone propionate 500 μg dry powder inhaler twice daily in patients with moderate asthma.
    Kupryś-Lipińska I; Tworek D; Vanderbist F; Bocheńska-Marciniak M; Kuna P
    Pneumonol Alergol Pol; 2013; 81(6):527-36. PubMed ID: 24142782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute cardiovascular safety of two formulations of beclometasone dipropionate/formoterol fumarate in COPD patients: A single-dose, randomised, placebo-controlled crossover study.
    Singh D; Ciurlia G; Piccinno A; Muraro A; Bocchi M; Scuri M
    Pulm Pharmacol Ther; 2017 Feb; 42():43-51. PubMed ID: 28065679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease.
    Reisner C; Fabbri LM; Kerwin EM; Fogarty C; Spangenthal S; Rabe KF; Ferguson GT; Martinez FJ; Donohue JF; Darken P; St Rose E; Orevillo C; Strom S; Fischer T; Golden M; Dwivedi S
    Respir Res; 2017 Jan; 18(1):8. PubMed ID: 28061907
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma.
    Oliver A; VanBuren S; Allen A; Hamilton M; Tombs L; Inamdar A; Kempsford R
    Clin Ther; 2014 Jun; 36(6):928-939.e1. PubMed ID: 24793536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The pharmacodynamics, pharmacokinetics, safety and tolerability of inhaled fluticasone furoate and vilanterol administered alone or simultaneously as fluticasone furoate/vilanterol.
    Kempsford R; Allen A; Bareille P; Hamilton M; Cheesbrough A
    Clin Pharmacol Drug Dev; 2015 Jan; 4(1):2-11. PubMed ID: 27127998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The ELLIPTA® Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers.
    Grant AC; Walker R; Hamilton M; Garrill K
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):474-85. PubMed ID: 26372466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of systemic absorption and bronchodilator effect of glycopyrronium bromide delivered by nebulizer or a dry powder inhaler in subjects with chronic obstructive pulmonary disease.
    Leaker BR; Singh D; Nicholson GC; Hezelova B; Goodin T; Ozol-Godfrey A; Galluppi G; Barnes PJ
    Respir Res; 2019 Jun; 20(1):132. PubMed ID: 31253162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of the Inhaled Selective Glucocorticoid Receptor Modulator AZD5423 Following Inhalation Using Different Devices.
    Melin J; Prothon S; Kloft C; Cleton A; Amilon C; Jorup C; Bäckman P; Olsson B; Hamrén UW
    AAPS J; 2017 May; 19(3):865-874. PubMed ID: 28281196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.
    Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a dry powder inhaler, the Ultrahaler, containing triamcinolone acetonide using in vitro-in vivo relationships.
    Lim JG; Shah B; Rohatagi S; Bell A
    Am J Ther; 2006; 13(1):32-42. PubMed ID: 16428920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of Bioequivalence Between the New Procaterol Hydrochloride Hydrate Dry Powder Inhaler and the Approved Dry Powder Inhaler in Patients With Asthma in a Randomized, Double-Blind, Double-Dummy, Crossover Comparison Study: A Phase 3 Study.
    Shirai R; Suzaki Y; Sato K; Takeuchi Y; Tokimatsu I; Koga N; Kadota J; Ohashi K
    Clin Pharmacol Drug Dev; 2018 May; 7(4):392-399. PubMed ID: 28884969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic Bioequivalence of Two Inhaled Tiotropium Bromide Formulations in Healthy Volunteers.
    Algorta J; Andrade L; Medina M; Kirkov V; Arsova S; Li F; Chi J
    Clin Drug Investig; 2016 Sep; 36(9):753-762. PubMed ID: 27470430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dry-Powder Inhaler Formulation of Rifampicin: An Improved Targeted Delivery System for Alveolar Tuberculosis.
    Rawal T; Kremer L; Halloum I; Butani S
    J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):388-398. PubMed ID: 28510480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.